Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Role of Calcitonin in Osteosclerosis of Myeloma?-Reply

Role of Calcitonin in Osteosclerosis of Myeloma?-Reply Abstract Unfortunately, the article of Rousseau et al came to our attention after our article was published in the Archives. Their observation of hypercalcitoninemia in osteosclerotic myeloma is interesting and may be important. It may mean that, in their patient, plasma cells were capable of producing and secreting CT. High plasma levels of CT were found in patients with cancer of the breast, cancer of the pancreas, oat cell carcinoma of the lung, and several other malignant neoplasms. In some, but not all of them, skeletal metastases were detected.1 However, the suggestion of Rousseau et al that hypercalcitoninemia may be responsible for osteosclerotic lesions in myeloma is debatable. According to Deftos,2 calcitonin inhibits bone resorption due to an inhibition of osteoclast activity. The evidence for promotion of bone formation is not conclusive and is even controversial. Certainly, patients with myeloma and osteosclerotic lesions may also have separate osteolytic lesions, References 1. Coombs RC, Hillyard C, Greenberg PB, et al: Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet 1:1080-1083, 1974.Crossref 2. Deftos LJ: Calcitonin in clinical medicine. Adv Intern Med 23:159-193, 1978. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Role of Calcitonin in Osteosclerosis of Myeloma?-Reply

Archives of Internal Medicine , Volume 140 (11) – Nov 1, 1980

Role of Calcitonin in Osteosclerosis of Myeloma?-Reply

Abstract

Abstract Unfortunately, the article of Rousseau et al came to our attention after our article was published in the Archives. Their observation of hypercalcitoninemia in osteosclerotic myeloma is interesting and may be important. It may mean that, in their patient, plasma cells were capable of producing and secreting CT. High plasma levels of CT were found in patients with cancer of the breast, cancer of the pancreas, oat cell carcinoma of the lung, and several other malignant neoplasms. In...
Loading next page...
 
/lp/american-medical-association/role-of-calcitonin-in-osteosclerosis-of-myeloma-reply-Jht0yYFgym

References (2)

Publisher
American Medical Association
Copyright
Copyright © 1980 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1980.00330220092040
Publisher site
See Article on Publisher Site

Abstract

Abstract Unfortunately, the article of Rousseau et al came to our attention after our article was published in the Archives. Their observation of hypercalcitoninemia in osteosclerotic myeloma is interesting and may be important. It may mean that, in their patient, plasma cells were capable of producing and secreting CT. High plasma levels of CT were found in patients with cancer of the breast, cancer of the pancreas, oat cell carcinoma of the lung, and several other malignant neoplasms. In some, but not all of them, skeletal metastases were detected.1 However, the suggestion of Rousseau et al that hypercalcitoninemia may be responsible for osteosclerotic lesions in myeloma is debatable. According to Deftos,2 calcitonin inhibits bone resorption due to an inhibition of osteoclast activity. The evidence for promotion of bone formation is not conclusive and is even controversial. Certainly, patients with myeloma and osteosclerotic lesions may also have separate osteolytic lesions, References 1. Coombs RC, Hillyard C, Greenberg PB, et al: Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet 1:1080-1083, 1974.Crossref 2. Deftos LJ: Calcitonin in clinical medicine. Adv Intern Med 23:159-193, 1978.

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Nov 1, 1980

There are no references for this article.